In WP1, a harmonized multi-cohort dataset (≈690 participants) was created, integrating clinical, dietary, proteomic, and metagenomic data. First in silico models identified candidate immune and nutritional biomarkers, and a validation cohort (comprising a cohort from Europe and from Asia) were assembled. In silico microbiome modelling identified diet-driven metabolic fingerprints relevant to metabolic health.
In WP2, the clinical protocol for the Precision Nutrition randomized controlled trial (RCT) was finalized and submitted to INSERM. Following extensive discussions with clinical partners, the screening and intervention phases were merged into a single streamlined design using routine inflammatory markers (CRP > 3 mg/L and E-DII ≥ 0). The Balanced-Immunity diet was defined as the core intervention model.
In WP3, an advanced immune and glyco-phenotyping was completed, including broad proteomic profiling (Olink) and initiating glycomic analyses in Bern.
In WP4, teams developed CRISPR and glycan-based cell models for future RCT-linked validation, and established mechanistic cellular models to study the effect of nutrients on modulation of immune response.
In WP5, a centralized database and secure analysis pipeline were implemented by SU, integrating all clinical and multi-omics datasets. Initial machine-learning and in silico analyses are ongoing, alsi in link with WP1
In WP6 ensured efficient project management, governance, and communication, with the website and DMP completed.
In WP7 launched anticipated valorisation activities, mapping exploitable assets (biomarkers, algorithms, digital tools) and initiating stakeholder engagement, also in link with EIC portfolio.
